Form 4: BridgeBio CEO Neil Kumar Receives Equity Grants

BridgeBio Pharma's CEO, Neil Kumar, was granted 40,570 stock options and 104,313 restricted stock units as part of his compensation.

Summary

• Neil Kumar, Chief Executive Officer, Director, and 10% Owner of BridgeBio Pharma, Inc. (BBIO), received equity awards on March 17, 2026.
• The awards include 40,570 stock options with an exercise price of $70.94 per share.
• The awards also include 104,313 Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• Both the stock options and RSUs will vest over time, with the first 1/16th vesting on May 16, 2026.
• Subsequent 1/16th portions of both awards will vest on a quarterly basis thereafter, subject to Mr. Kumar's continued service with BridgeBio Pharma or its subsidiaries.
• The stock options have an expiration date of March 16, 2036, while the RSUs have no expiration date.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-arranged.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and healthy practice for corporate governance.

Positives

• The grants align the CEO's interests with long-term shareholder value through significant equity ownership.
• The substantial equity awards demonstrate continued commitment to the CEO's role and the company's future strategic direction.

Future Outlook

No forward-looking statements or guidance regarding company performance are provided in this filing, beyond the vesting schedule tied to continued service.

Industry Context

StockSavvy.ai notes that equity grants, particularly RSUs and stock options with multi-year vesting schedules, are standard practice in the biotechnology and pharmaceutical industries for executive compensation. This structure aims to incentivize long-term performance and retention, aligning executive interests with shareholder value creation.

Comparison to Industry Standards

• Equity compensation packages for CEOs in the biotech sector often include a mix of stock options and restricted stock units, similar to the grants received by Neil Kumar.
• Comparable companies like Moderna or BioNTech frequently utilize similar long-term incentive structures to retain top talent and drive innovation.
• The specific value and vesting schedule would need to be compared against peer group compensation reports (e.g., proxy statements) to assess if it's within industry norms, but the type of compensation is standard.

Corporate Governance

Related Party Transactions

• Equity grants of 40,570 stock options and 104,313 Restricted Stock Units were made to Neil Kumar, the Chief Executive Officer, Director, and 10% Owner of BridgeBio Pharma, Inc.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term company performance.
• Management: The CEO receives significant long-term incentives, reinforcing commitment to the company's success.

Next Steps

• Vesting of 1/16th of stock options and RSUs on May 16, 2026.
• Subsequent quarterly vesting of 1/16th of stock options and RSUs.
• Continued service of Neil Kumar with BridgeBio Pharma or its subsidiaries.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Neil Kumar, CEO, Stock Options, Restricted Stock Units, RSUs, Equity Grant, Insider Transaction, Form 4, Compensation, Executive Compensation, Rule 10b5-1